Summary: Peerbridge Health, known for its AI-powered ambulatory ECG monitor capable of detecting obstructive sleep apnea (OSA) and heart conditions, has been selected to participate in the 2024 HeartX Cardiovascular Accelerator program. The program provides startups with access to hospital pilot projects and clinical trials to advance cardiovascular innovations. Peerbridge joins three other startups—Caristo, Haermonics, and MultiplAI Health—for the 2024 HeartX program.
Three Key Takeaways:
- Peerbridge’s ECG Monitor Detects OSA and Heart Conditions: Peerbridge’s Cor device uses AI and advanced signal fidelity to detect sleep apnea, heart failure, ejection fraction, and 31 arrhythmias.
- HeartX Provides Support for Early-Stage Companies: The HeartX program gives selected companies $150,000 in investment capital and access to clinical trials and hospital pilot projects to further their innovations.
- Peerbridge Among Four Startups Selected: Peerbridge is joined by Caristo, Haermonics, and MultiplAI Health, which focus on coronary inflammation, post-operative bleeding management, and AI-powered diagnostics, respectively.
Peerbridge Health, maker of an ambulatory ECG monitor capable of detecting obstructive sleep apnea (OSA) and heart conditions, is among four companies chosen to participate in the 2024 HeartX Cardiovascular Accelerator program.
Cor, Peerbridge’s ECG device, merges artificial intelligence with advanced signal fidelity to detect heart failure, determine ejection fraction, diagnose sleep apnea, and identify 31 arrhythmias. The Cor is reimbursable under standard ECG codes.
Alongside Peerbridge, the three other companies selected are Caristo, specializing in coronary inflammation detection; Haermonics, focusing on post-operative bleeding management; and MultiplAI Health, advancing AI-powered precision diagnostics.
HeartX Program Supports Startups
HeartX, powered by HealthTech Arkansas and MedAxiom—along with other cardiology practices around the country—is a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations to market. Representatives from over two dozen cardiology programs participated in the selection process.
“We are thrilled to welcome this year’s cohort of innovative companies to the HeartX program,” says Jeff Stinson, director of HealthTech Arkansas, in a release. “Each of these startups brings groundbreaking technology that has the potential to transform cardiovascular care. Through our unique model, which guarantees pilot projects and clinical trials with leading healthcare providers, we are confident that these companies will make a significant impact in advancing heart health.”
Each company will receive $150,000 in investment capital and full access to clinicians and administrators while executing their pilot projects and clinical studies in the HeartX program.
Photo caption: Peerbrige Cor
File photo
Leave a Reply